Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Five Spanish Hospitals start international phase III clinical trial with H5N1 influenza pandemic vaccine

05.05.2006


Both governments and the scientific community are mobilised to face the threat of a possible pandemic provoked by avian influenza. Whereas there is no need to alarm the population, we must design tools in order to fight influenza in case it develops. According to historical data and to the high genetic variability of influenza virus, the development of this pandemic is only a matter of time and that the appropriate circumstances are given.



The H5N1 virus, which affects the European fowl, has already evidenced that it could successfully break the human barrier. This is the reason why H5N1 is the best candidate to establish the bases of the development of pandemic vaccines. Five large national hospitals will participate in the first study with a H5N1 influenza pandemic vaccine held in Spain. Our specialists are working in an international study, with the participation of 7 countries, in order to assess the possible side effects and immunogenicity of this vaccine, developed by GlaxoSmithKline (GSK), in individuals over 18 years.

A total of 5,052 individuals will participate in this study, 1,500 of which will be recruited in Spain. The five Spanish centres are Hospital 12 de Octubre, Hospital Clínico San Carlos and Hospital de La Princesa in Madrid, and the centres Hospital Vall d’Hebrón and Hospital Clínic in Barcelona. People participating in the study will be randomly separated into two groups: 75% will receive two doses of influenza vaccine, and 25% will receive a dose of conventional influenza vaccine and a dose of placebo. The second dose will be administrated after 21 days after the first medical examination, and during the study, two more examinations will have place (days 43 and 180) and a telephone check (day 51). In 10% of volunteers, blood tests will be made in order to analyse the immune response triggered by the vaccine.


Furthermore, participants will fill in a monitoring card during the week after the administration of each dose, where the potential side effects that could appear, such as pain in the injection area or fever, frequent after any type of vaccination, will be noted. This study has been approved by the Ethics Committees of Clinical Research of the five hospitals and also by the Spanish Agency of Drugs and Health Products.

This vaccine is fractionated, since it only contains parts of the viral proteins which activate our immune system. Since no complete virus is administrated, it is impossible that this vaccine could cause influenza. The vaccine includes an adjuvant, similar to that used by GSK in the malaria vaccine that Hospital Clínic is testing in Mozambique, which enhances the immunogenic effects of the vaccine. The stimulation of the immune system caused by this adjuvant, has already proved successful as a part of a vaccine against conventional influenza, and permits to reduce the antigen concentration administered in each vaccination. In the hypothesis of a pandemic, we must take into account that it would be necessary to vaccinate a large amount of population, and the rhythm of production of vaccines is limited.

The efforts are focused in the development of strategies for vaccine production. Last, this vaccine has been produced following the recommendations of the WHO, so that the H5N1 virus has been recombined with the H1N1 Puerto Rico strain of 1934. This strain is highly stable and promotes the development of vaccines in chicken embryo.

The nomenclature of the several influenza virus identifies the variant they contain of the two more important genes involved in the infection. The Haemaglutinin (H) gene is related with the infectiousness and the virulence of the virus, whereas the Neuraminidase (N) gene determines the ability of progression of the infection. Genetic material of the virus is highly variable and it is found as fractionated single-strained RNA. Small changes in the H and N genes create viruses which cause the frequent annual influenza epidemic. When a large change is produced or a new version of the gene appears, an antigenic change is capable of triggering a worldwide epidemic, called pandemic.

Influenza virus with a pandemic potential could appear by direct transfer of an animal virus to humans, -as happened in the “Spanish Influenza” that in 1918 caused death to 5% of the world population- or by a genetic reassortment between human and animal viruses. Such genetic reassortment would have place in a host co-infected by two different viruses.

The probability that a pandemic human virus is generated is now low, but the risk exists, and it is increased when cases of animal flu are found in humas, such in the case of H5N1. The hundred of death cases documented until now can give an idea of the potential danger we are facing.

Furthermore, there are two circumstances that worsen this situation: this virus can mutate rapidly, and the fowl surviving the infection excrete the virus intensely through respiratory secretions and faeces during at least 10 days. Because of all this, it is important to make a both scientific and economic effort in order to obtain the best weapons to combat a possible definitive adaptation to humans of the H5N1 virus. In any case, this effort led by Spain, Germany, Holland, Sweden, Russia, France and Estonia will permit to improve the available tools in order to face this or future pandemics.

Àlex Argemí Saburit | alfa
Further information:
http://www.clinic.ub.es
http://www.idibaps.ub.edu

More articles from Health and Medicine:

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

nachricht Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: BAM@Hannover Messe: innovative 3D printing method for space flight

At the Hannover Messe 2018, the Bundesanstalt für Materialforschung und-prüfung (BAM) will show how, in the future, astronauts could produce their own tools or spare parts in zero gravity using 3D printing. This will reduce, weight and transport costs for space missions. Visitors can experience the innovative additive manufacturing process live at the fair.

Powder-based additive manufacturing in zero gravity is the name of the project in which a component is produced by applying metallic powder layers and then...

Im Focus: Molecules Brilliantly Illuminated

Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.

Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Getting electrons to move in a semiconductor

25.04.2018 | Physics and Astronomy

Reconstructing what makes us tick

25.04.2018 | Physics and Astronomy

Cheap 3-D printer can produce self-folding materials

25.04.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>